Jun 25 |
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
|
Jun 10 |
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
|
Jun 6 |
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
|
May 28 |
7 Penny Biotech Stocks to Triple Your Investment
|
May 21 |
Here's Why Momentum in Lipocine (LPCN) Should Keep going
|
May 9 |
Lipocine GAAP EPS of $0.66, revenue of $7.62M
|
May 9 |
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
|
May 8 |
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
|
May 1 |
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
|
Apr 11 |
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
|